Pro-Leu-Gly-NH2

Modify Date: 2024-01-02 12:47:04

Pro-Leu-Gly-NH2 structure	Common Name	Pro-Leu-Gly-NH2
	CAS Number	2002-44-0	Molecular Weight	284.35500
	Density	1.147g/cm3	Boiling Point	626.2ºC at 760mmHg
	Molecular Formula	C₁₃H₂₄N₄O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	332.5ºC

Use of Pro-Leu-Gly-NH2

MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects of morphine and stress-induced analgesia (SIA). MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB)[1][2][3].

Name	(2S)-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
Synonym	More Synonyms

Description	MIF-1 (Melanostatin), an endogenous brain peptide, is a potent dopamine receptor allosteric modulator. MIF-1 inhibits melanin formation. MIF-1 blocks the effects of opioid receptor activation to modulate the analgesic effects of morphine and stress-induced analgesia (SIA). MIF-1 accesses from the blood to the CNS by directly crossing the blood-brain barrier (BBB)[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
In Vitro	MIF-1 (Melanostatin, 1 μM) provokes a reversible hyperpolarization and a suppression of spontaneous action potentials[2].
In Vivo	MIF-1 (Melanostatin, 1 mg/kg; i.p.; once, for 1 hour; male Wistar rats) modulates the analgesic effects of morphine and stress-induced analgesia (SIA)[1]. MIF-1 (Melanostatin, 1 mg/kg; i.p.; daily, for 8 weeks; Sprague-Dawley rats) attenuates spiroperidol-induced impairment of development of striatal dopamine D2 receptors in rats[3]. Animal Model: Male Wistar rats[1] Dosage: 1 mg/kg Administration: Intraperitoneal injection; once, for 1 hour Result: Decreased the analgesic effect of morphine. Increased the pain threshold for at least 1 h. Animal Model: Sprague-Dawley rats[3] Dosage: 1 mg/kg Administration: Intraperitoneal injection; daily, for 8 weeks Result: Attenuated the ontogenic impairment of striatal D2 receptors that was produced by spiroperidol (HY-B1371) treatment.
References	[1]. Bocheva A, et, al. Antiopioid properties of the TYR-MIF-1 family. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):673-7. [2]. Valentijn JA, et, al. Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents. J Physiol. 1994 Mar 1;475(2):185-95. [3]. Saleh MI, et, al. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny. Peptides. 1989 Jan-Feb;10(1):35-9.

Density	1.147g/cm3
Boiling Point	626.2ºC at 760mmHg
Molecular Formula	C₁₃H₂₄N₄O₃
Molecular Weight	284.35500
Flash Point	332.5ºC
Exact Mass	284.18500
PSA	113.32000
LogP	0.68170
Vapour Pressure	1.34E-15mmHg at 25°C
Index of Refraction	1.51